Shaopeng Wei

Title: The Innovative Contributions of Shaopeng Wei

Introduction

Shaopeng Wei is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target tumor growth. His work is characterized by a focus on innovative solutions for cancer treatment.

Latest Patents

Shaopeng Wei holds a patent for a "Methylacryloyl benzimidazolone derivative and anti-tumour use thereof." This patent discloses the use of a methylacryloyl benzimidazolone derivative, an optical isomer, or a pharmaceutically acceptable salt or prodrug in the preparation of pharmaceutical compositions. These compositions are designed to down-regulate the activity of PI3K/Akt pathways, treat or inhibit tumors, and block the cell cycle. The compounds involved can effectively down-regulate Akt phosphorylation levels in the PI3K/Akt signaling pathways. Notably, the functional effects of these compounds are comparable to those of the small-molecular targeting drug MK2206. However, the derivatives represented by FD1 demonstrate superior effects on PTEN deleted cells, showcasing their potential in cancer therapy.

Career Highlights

Throughout his career, Shaopeng Wei has worked with various companies, including Shanghai Nature Standard R&D and Biotech Co., Ltd. and Shanghai Standard Technology Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical research and development.

Collaborations

Shaopeng Wei has collaborated with notable colleagues such as Jiapeng Li and Zhiqin Ji. These partnerships have likely enhanced his research capabilities and broadened the impact of his inventions.

Conclusion

Shaopeng Wei's innovative work in the field of pharmaceuticals, particularly in cancer treatment, highlights his significant contributions as an inventor. His patent for the methylacryloyl benzimidazolone derivative represents a promising advancement in the fight against tumors.